MedPredict Publishes Two New Reports Providing Expert Analysis of Malignant Hematology Drug Development
The first report, entitled "Thought Leader Insight & Analysis - AML/MDS," focuses on acute myelogenous leukemia and myelodysplastic syndrome. "This report highlights the most important data presented at ASH, and clarifies the ways these data will change clinical practice," according to Jeff Berk, MedPredict president. "A key emphasis of this report is transplant, and how pharmaceuticals and biologicals better prepare patients for transplant. Our thought leader panel discusses how to achieve complete responses, how they are thinking about combination therapy, and new ways for attacking quiescent malignant stem cells."
The second report, entitled "Thought Leader Insight & Analysis - Multiple Myeloma/Lymphoma," focuses on how the clinical data presented at ASH is likely to translate into changing treatment paradigms. "This report brings together the diverse perspectives of experts who grapple with a wide spectrum of issues related to these hematologic malignancies, including clinical pathology, community based patients, tertiary care treatment, and medical oncology from the strategic vantage point of clinical commercial development," said Berk.
Topics this report addresses include:
Companies mentioned in these reports include: Allos, Amgen, Bayer-Schering, Biogen Idec, BMS (Kosan), Celgene, Cell Therapeutics, Cephalon, Eisai, Genentech, Genmab, Genzyme, Geron, GSK, Gloucester, ImmunoGen, Incyte, Keryx, Mayo Scottsdale, Merck, Nereus, Novartis, PDL Biopharma, Proteolix, Rigel, Roche, Seattle Genetics, Takeda/Millennium, Vion, Wyeth, Xencor.
This report can be purchased by contacting MedPredict (www.medpredict.com).
MedPredict maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.
-- Reimbursement: oral vs. parenteral; induction vs. maintenance. -- Multiple myeloma/lymphoma treatment strategies, including: - transplant eligible/non-transplant eligible; - induction/maintenance; - doublets/triplets; - community/tertiary care; - +65 years old/younger; and - approval pathways.
You May Also Like